Jianguo Xu

Dr. Jianguo Xu


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2023 in International Journal of Surgery
Verified
Journal Article
Open access
XZXin Zhang
Xin Zhang
KYKang Yi
Kang Yi
JXJianguo Xu
Jianguo Xu
WWWen-Xin Wang
Wen-Xin Wang
CLCheng-Fei Liu
Cheng-Fei Liu
TYTao You
Tao You
Aim: This paper aimed to explore the application of three-dimensional (3D) printing in cardiovascular diseases, to reach an insight in this field and prospect the future trend. Methods: The articles were selected from the Web of Science Core Collection database. Excel 2019, VOSviewer 1.6.16, and CiteSpace 6.1.R6 were used to analyze the information. Results: A total of 467 papers of 3D printing in cardiovascular diseases were identified, and the first included literature appeared in 2000. A total of 692 institutions from 52 countries participated in the relevant research, while the United States of America contributed to 160 articles and were in a leading position. The most productive institution was Curtin University , and Zhonghua Sun who has posted the most articles (n=8) was also from there. The Frontiers in Cardiovascular Medicine published most papers (n=25). The Journal of Thoracic and Cardiovascular Surgery coveted the most citations (n=520). Related topics of frontiers will still focus on congenital heart disease, valvular heart disease, and left atrial appendage closure. Conclusions: The authors summarized the publication information of the application of 3D printing in cardiovascular diseases related literature from 2000 to 2023, including country and institution of origin, authors, and publication journal. This study can reflect the current hotspots and novel directions for the application of 3D printing in cardiovascular diseases.


8 June 2023 in International Journal of Surgery
Verified
Journal Article
Open access
KYKang Yi
Kang Yi
WWWei Wang
Wei Wang
JXJianguo Xu
Jianguo Xu
XZXin Zhang
Xin Zhang
WWWenxin Wang
Wenxin Wang
TYTao You
Tao You
Background: Uncertainties persist about whether to aggressively and effectively treat tricuspid regurgitation (TR) during mitral valve (MV) surgery. Review methods: Systematic literature searches were performed in five databases to collect all relevant studies published before May 2022 on whether the tricuspid valve (TV) was treated during MV surgery. Separate meta-analyses were performed on data from Unmatched studies and Randomized controlled trials (RCT)/Adjusted studies. Main Results: A total of 44 publications were included, of which eight were RCT studies and the rest were retrospective studies. There was no difference in 30-day mortality [odds ratio (OR): 1.00, 95% confidence interval (95%CI): 0.71–1.42, OR: 0.66, 95%CI: 0.30–1.41)] or overall survival [hazard ratio (HR): 1.01, 95%CI: 0.85–1.19, HR: 0.77, 95%CI: 0.52–1.14] in Unmatched studies and RCT/Adjusted studies. Late mortality (OR: 0.37, 95%CI: 0.21-0.64) and cardiac-related mortality (OR: 0.36, 95%CI: 0.21–0.62) were lower in the TV repair (TVR) group in the RCT/Adjusted studies. In the Unmatched studies, overall cardiac mortality (OR: 0.48, 95%CI: 0.26–0.88) was lower in the TVR group. In the late TR progression analysis, the late TR progression was lower among patients in the concomitantly intervened tricuspid group, and patients in the untreated tricuspid group were prone to TR progression in both studies (HR: 0.30, 95%CI: 0.22–0.41, HR: 0.37, 95%CI: 0.23–0.58). Conclusions: TVR concomitant with MV surgery is most effective in patients with significant TR and dilated tricuspid annulus, especially those with a significantly reduced risk of distant TR progression. Systematic Review Registration: PROSPERO, identifier: CRD42022380967.

18 February 2025 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Closed access
PDF file
JXJianguo Xu
Jianguo Xu
QZQingyong Zheng
Qingyong Zheng
YCYating Cui
Yating Cui
JWJunfei Wang
Junfei Wang
YXYafei Xie
Yafei Xie
JTJinhui Tian
Jinhui Tian

12 June 2026 in Medicine
Verified
Journal Article
Open access
BZBowen Zhang
Bowen Zhang
JXJianguo Xu
Jianguo Xu
KYKelu Yang
Kelu Yang
LYLiping Yu
Liping Yu
QZQingyong Zheng
Qingyong Zheng
JSJuling Sun
Juling Sun
Background: The integration of blockchain technology in healthcare has garnered significant global interest, showing promising potential for revolutionizing this vital sector. This study presents a comprehensive analysis of blockchain-related publications in healthcare, aiming to offer an in-depth understanding of the field and forecast emerging trends. Material and methods: We employed the Web of Science Core Collection as our primary database for sourcing relevant literature. The data was meticulously analyzed using advanced tools such as VOSviewer 1.6.9, Bibliometrix 3.1.4, and CiteSpace 5.7.R2. Results: Our bibliometric analysis identified 218 scholarly articles on blockchain in healthcare since its first emergence in 2016. The research involved 683 institutions across 55 countries, with China and the United States leading in research output (> 90 publications each). The University of California, San Diego demonstrated the highest institutional productivity (n = 13). While the Journal of Medical Internet Research led in publication volume (39), Institute of Electrical and Electronics Engineers Access emerged as the most co-cited journal (654 citations). Thematic analysis revealed 6 major research clusters: personal health record systems, coranavirus disease 2019 response applications, remote healthcare services, security and privacy frameworks, implementation schemes and models, and smart contract development. Conclusions: The research landscape of blockchain in healthcare demonstrates rapid growth and increasing international collaboration. Current research frontiers focus on developing secure and privacy-preserving frameworks, particularly in health data management and pandemic response solutions, indicating promising directions for future healthcare transformation.

1 August 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
JXJianguo Xu
Jianguo Xu
DYDonghua Yang
Donghua Yang
QZQingyong Zheng
Qingyong Zheng
TLTengfei Li
Tengfei Li
YCYating Cui
Yating Cui
JTJinhui Tian
Jinhui Tian
Background: Staphylococcus aureus, including methicillin-resistant lineages, is a leading cause of device- and catheter-related infection, and rising resistance motivates the search for antimicrobial peptides (AMPs) with strong anti-staphylococcal activity and low host toxicity. Machine learning can prioritize candidate peptides. However, the literature-derived AMP datasets are prone to homology-driven optimism, and computational studies frequently overstate their translational reach. Methods: We curated 4007 deduplicated S. aureus-active AMP records and 582 binary-labeled hemolysis records. Each peptide was encoded with a transparent 538-dimensional physicochemical and compositional feature vector. Five classifiers and five regressors were evaluated for four endpoints (potency classification, log10 MIC regression, hemolysis classification, normalized hemolytic index) under both conventional random 5-fold cross-validation and homology-aware cross-validation, in which sequences were clustered by 3-mer similarity and whole clusters were confined to single folds. Class imbalance was handled by class weighting. Model behavior was interpreted with SHAP and Fisher-exact k-mer enrichment, and candidates were ranked by a multi-objective score that combines the independently trained heads. Results: Under homology-aware validation, performance was lower than under random splitting, as expected. Potency classification reached an AUROC of about 0.71 (Random Forest), compared with 0.797 under random cross-validation. Hemolysis classification remained strong at AUROC 0.90 (95% CI 0.88 to 0.93), which indicates that its high accuracy is not a homology leakage artifact. MIC regression was modest (homology-aware R2 0.17, Spearman ρ 0.39) and is therefore treated only as a rank-ordering signal. SHAP and k-mer analyses recovered interpretable structure–activity relationships. Net positive charge and amphipathicity drove potency, whereas bulk hydrophobicity drove hemolysis. Applying the pipeline to a generated pool prioritized 20 candidates. Nearest-neighbor analysis shows that these are close optimized variants of known potent scaffolds, with a median identity of 95% to a known peptide, rather than novel sequences. Conclusions: We present an interpretable, honestly benchmarked multi-objective pipeline that optimizes known anti-S. aureus AMP scaffolds toward lower predicted hemolysis. The prioritized peptides are computational hypotheses for future synthesis and experimental testing. Their low predicted hemolysis reflects a selection criterion rather than validated safety, and cross-species selectivity was not assessed.